Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Trial Status: active

This phase II trail tests how well agenT-797 with botensilimab, balstilimab, ramucirumab and paclitaxel works in treating patients with esophagogastric cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic). AgenT-797 is a cellular therapy made up of invariant natural killer T cells (iNKT cells) from healthy donors. The iNKT cells help directly kill cancer cells and activate the immune system, which may help other immune cells kill cancer cells. Botensilimab and balstilimab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Giving agenT-797 with botensilimab, balstilimab, ramucirumab and paclitaxel may work better to treat patients with advanced unresectable or metastatic esophagogastric cancer.